Comparative Pharmacology
Head-to-head clinical analysis: PENTIDS 800 versus PIPERACILLIN AND TAZOBACTAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENTIDS 800 versus PIPERACILLIN AND TAZOBACTAM.
PENTIDS '800' vs PIPERACILLIN AND TAZOBACTAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin G is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), transpeptidases that catalyze the final transpeptidation step of peptidoglycan cross-linking, leading to cell lysis.
Piperacillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), while tazobactam is a beta-lactamase inhibitor that protects piperacillin from degradation by beta-lactamases.
800 mg orally every 6 to 8 hours; maximum 4 g per day.
3.375 g (piperacillin 3 g + tazobactam 0.375 g) IV every 6 hours, or 4.5 g (piperacillin 4 g + tazobactam 0.5 g) IV every 8 hours for nosocomial pneumonia.
None Documented
None Documented
0.5-1 hour; prolonged to 2-5 hours in renal impairment.
Piperacillin ~0.7–1.2 h, tazobactam ~0.7–1.5 h; prolonged in renal impairment (piperacillin up to 3.3 h, tazobactam up to 5.6 h in severe impairment).
Renal: ~60-85% unchanged via glomerular filtration and tubular secretion; Biliary: ~10%; Fecal: <5%.
Primarily renal: piperacillin ~68% unchanged, tazobactam ~80% unchanged; biliary excretion <10%; fecal <1%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic / Beta-Lactamase Inhibitor Combination